Apilimod

Apilimod
Clinical data
Trade namesApilimod
Legal status
Legal status
Identifiers
  • N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ECHA InfoCard100.237.985 Edit this at Wikidata
Chemical and physical data
FormulaC23H26N6O2
Molar mass418.501 g·mol−1
3D model (JSmol)
  • CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4
  • InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+
  • Key:HSKAZIJJKRAJAV-KOEQRZSOSA-N

Apilimod (STA-5326) is a drug that was initially identified as an inhibitor of production of the interleukins IL-12 and IL-23, and developed for the oral treatment of autoimmune conditions such as Crohn's disease and rheumatoid arthritis,[1] though clinical trial results were disappointing and development for these applications was not continued.[2][3]

Subsequently, it was discovered that apilimod has an additional mode of action, as an inhibitor of the lipid kinase enzyme PIKfyve.[4][5] PIKfyve makes two lipids, PtdIns5P and PtdIns(3,5)P2, whose syntheses are efficiently and similarly inhibited by apilimod (ID50 = 0.4 nM) in in vitro assays. Administration of apilimod (100 nM; 60 min) in human embryonic kidney cells powerfully reduces levels of both PtdIns5P and PtdIns(3,5)P2.[6]

Recently apilimod has been repurposed as a potential antiviral and anti-cancer drug, with possible applications in the treatment of non-Hodgkin lymphoma as well as viral diseases such as Ebola virus disease, Lassa fever and COVID-19.[7][8][9][10][11]

References

  1. ^ Billich A (January 2007). "Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency". IDrugs. 10 (1): 53–9. PMID 17187316.
  2. ^ Sands BE, Jacobson EW, Sylwestrowicz T, Younes Z, Dryden G, Fedorak R, Greenbloom S (July 2010). "Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease". Inflammatory Bowel Diseases. 16 (7): 1209–18. doi:10.1002/ibd.21159. PMID 19918967. S2CID 26012456.
  3. ^ Krausz S, Boumans MJ, Gerlag DM, Lufkin J, van Kuijk AW, Bakker A, et al. (June 2012). "Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis". Arthritis and Rheumatism. 64 (6): 1750–5. doi:10.1002/art.34339. PMID 22170479.
  4. ^ Shisheva A, Sbrissa D, Ikonomov O (1999). "Cloning, characterization, and expression of a novel Zn2+-binding FYVE finger-containing phosphoinositide kinase in insulin-sensitive cells". Molecular and Cellular Biology. 19 (1): 623–634. doi:10.1128/mcb.19.1.623. PMC 83920. PMID 9858586.
  5. ^ Cai X, Xu Y, Cheung AK, Tomlinson RC, Alcázar-Román A, Murphy L, et al. (July 2013). "PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling". Chemistry & Biology. 20 (7): 912–21. doi:10.1016/j.chembiol.2013.05.010. PMC 4878021. PMID 23890009.
  6. ^ Sbrissa D, Naisan G, Ikonomov OC, Shisheva A (September 2018). "Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation". PLOS ONE. 13 (9) e0204532. Bibcode:2018PLoSO..1304532S. doi:10.1371/journal.pone.0204532. PMC 6150535. PMID 30240452.
  7. ^ Gayle S, Landrette S, Beeharry N, Conrad C, Hernandez M, Beckett P, et al. (March 2017). "Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma". Blood. 129 (13): 1768–1778. doi:10.1182/blood-2016-09-736892. PMC 5766845. PMID 28104689.
  8. ^ Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, et al. (April 2017). "The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection". PLOS Neglected Tropical Diseases. 11 (4) e0005540. doi:10.1371/journal.pntd.0005540. PMC 5402990. PMID 28403145.
  9. ^ Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, et al. (April 2019). "Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses". Journal of Virology. 93 (8). doi:10.1128/JVI.02185-18. PMC 6450122. PMID 30700611.
  10. ^ Ikonomov OC, Sbrissa D, Shisheva A (November 2019). "Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations". Toxicology and Applied Pharmacology. 383 114771. doi:10.1016/j.taap.2019.114771. PMID 31628917.
  11. ^ "Researchers use live virus to identify 30 existing drugs that could treat COVID-19 | SBP". www.sbpdiscovery.org. Retrieved 2020-04-20.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.